137 related articles for article (PubMed ID: 10098948)
21. Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs.
Baniel J; Israilov S; Engelstein D; Shmueli J; Segenreich E; Livne PM
Urology; 2000 Oct; 56(4):647-52. PubMed ID: 11018623
[TBL] [Abstract][Full Text] [Related]
22. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
[TBL] [Abstract][Full Text] [Related]
23. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
Lee LM; Stevenson RW; Szasz G
J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
[TBL] [Abstract][Full Text] [Related]
24. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction.
Montorsi F; Guazzoni G; Bergamaschi F; Ferini-Strambi L; Barbieri L; Rigatti P
J Urol; 1993 May; 149(5 Pt 2):1291-5. PubMed ID: 7683061
[TBL] [Abstract][Full Text] [Related]
25. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
Kattan S; Collins JP; Mohr D
Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction.
Lammers PI; Rubio-Aurioles E; Castell R; Castaneda J; Ponce de Leon R; Hurley D; Lipezker M; Loehr LA; Lowrey F
Int J Impot Res; 2002 Feb; 14(1):54-9; discussion 60. PubMed ID: 11896479
[TBL] [Abstract][Full Text] [Related]
28. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
[TBL] [Abstract][Full Text] [Related]
29. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
Chao R; Clowers DE
Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
[TBL] [Abstract][Full Text] [Related]
30. Use of prostaglandin E1 for papaverine-failed erections.
Reiss H
Urology; 1989 Jan; 33(1):15-6. PubMed ID: 2911923
[TBL] [Abstract][Full Text] [Related]
31. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
Kiely EA; Bloom SR; Williams G
Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine.
Zentgraf M; Baccouche M; Jünemann KP
Urol Int; 1988; 43(2):65-75. PubMed ID: 3291360
[TBL] [Abstract][Full Text] [Related]
33. Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic.
Armstrong DK; Convery A; Dinsmore WW
Int J STD AIDS; 1993; 4(4):214-6. PubMed ID: 8399501
[TBL] [Abstract][Full Text] [Related]
34. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
Tang SF; Chu NK; Wong MK
Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
[TBL] [Abstract][Full Text] [Related]
35. Experience with triple-drug therapy in a pharmacological erection program.
Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
[TBL] [Abstract][Full Text] [Related]
36. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
Waldhauser M; Schramek P
J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
[TBL] [Abstract][Full Text] [Related]
37. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
[TBL] [Abstract][Full Text] [Related]
38. Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis.
Chochina L; Naudet F; Chéhensse C; Manunta A; Damphousse M; Bonan I; Giuliano F
Sex Med Rev; 2016 Jul; 4(3):257-269. PubMed ID: 27871959
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
[TBL] [Abstract][Full Text] [Related]
40. Penile function following intracavernosal injection of vasoactive agents or saline.
Kiely EA; Ignotus P; Williams G
Br J Urol; 1987 May; 59(5):473-6. PubMed ID: 3594105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
